Diagnosis of Primary Hepatic Lymphoma in a 55-Year-Old Male Patient Presented With Pain in the Right Hypochondrium: A Very Rare Case

Furqan Ul Haq 1, Said Amin 1, Hamza Yunus 1, Basharat Ullah 1, Wajid Ali 1

1. Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK

Corresponding author: Furqan Ul Haq, furqanulhaq459@gmail.com

Abstract

Primary hepatic lymphoma (PHL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL). A 55-year-old male patient presented to us with jaundice and right upper quadrant pain. Investigations showed elevated alkaline phosphatase, lactate dehydrogenase, total bilirubin, normal alanine transaminase, and negative viral profile. Sonographic and computed tomographic scans show hepatosplenomegaly with hypodense lesion in liver associated with lymph nodes enlargement in the region of porta hepatis celiac axis, mediastinal and axillary lymphadenopathy. On immunohistochemistry, cells were positive for cluster of differentiation (CD)-19, CD-20, CD-21, c-myelocytomatosis oncogene (c-MYC), B-cell lymphoma 2 (Bcl-2), multiple myeloma oncogene-1 (MUM-1), same as B cell markers so it is diagnosed as PHL. DLBCL especially PHL shall be considered among the differentials of space-occupying lesions of liver. Early diagnosis of primary hepatic lymphoma is not a difficult task if excisional lymph node biopsy is taken following detection on ultrasound or CT scan which will lead to improved treatment, improvement in survival, and cost-effectiveness with good prognostic outcomes.

Introduction

Primary hepatic lymphoma (PHL) is a hepatic presentation of diffuse large B-cell lymphoma (DLBCL). Among all non-Hodgkin’s lymphoma (NHL) cases, the DLBCL comprises 30-40% of cases [1]. DLBCL is predominantly common in the sixth or seventh decade of life [2]. It presents itself in two forms - nodal DLBCL and extranodal DLBCL. The nodal DLBCL presents mainly in the lymph nodes (64.8%), Waldeyer’s ring (19.7%), mediastinum (12.8%), and the spleen (2.7%). Extranodal DLBCL involves stomach (22.4%), intestines (16%), nose and sinuses (8.5%), testis (8.4%), skin (7.9%), thyroid (6.9%), and CNS (6.4%), etc. while DLBCL involving the liver is a very rare type comprising only 0.4% [3]. Because of the very non-specific presentation of DLBCL involving the liver, its diagnosis becomes challenging clinically and the need for excisional biopsy of the liver and sub-hepatic lymph nodes is highly important in establishing a specific diagnosis. This case depicts this unique presentation involving the liver and emphasizes the role of clinical symptoms and histopathological features suggestive of hepatic DLBCL which will help in detecting the disease at earlier stages and improve the survival rate, cost-effective health care, and better long-term prognosis.

Case Presentation

This 55-year-old patient was presented on November 8, 2021, with swelling and non-colicky pain in the right hypochondrium. It was associated with intermittent low-grade fever, night sweats, and weight loss from the past four months. There was anorexia but no vomiting, loose stool, or pain aggravation on eating. The patient also reported generalized body weakness affecting his daily activities. His physical examination was remarkable for mild jaundice and pallor, mild-to-moderate tenderness in the right hypochondrium, hepatomegaly of 15.5 cm, and splenomegaly of 11 cm in its largest diameter. Investigations done are given below in Table 1.
### TABLE 1: Laboratory outcomes for the patient.

| S.n. | Entity of investigation | Results | Normal range |
|------|-------------------------|---------|--------------|
| 1.   | TLC                     | 5.63x10³/uL | 4-11x10³/uL |
| 2.   | DLC                     | Neutrophils 77% | 40-70% |
|      |                         | Lymphocytes 7.9% | 20-25% |
|      |                         | Monocytes 14% | 2-10% |
| 3.   | Hemoglobin              | 9.21 g/dL | 12.5-16.5 g/dL |
| 4.   | Hematocrit              | 22.5% | 36-54% |
| 5.   | RDW%                    | 21.8% | 11.5-14.5% |
| 6.   | Platelets               | 118x10³/uL | 150-400x10³/uL |
| 7.   | Serum total bilirubin   | 2.4 mg/dL | 0.1-1.2 mg/dL |
| 8.   | Alkaline phosphatase    | 312 u/L | 44-147 IU/L |
| 9.   | Serum albumin           | 2.4 g/dL | 3.4-5.4 g/dL |
| 10.  | Lactate dehydrogenase   | 341 U/L | 140-280 U/L |
| 11.  | Serum uric acid         | 4.4 mg/dL | 3.4-7.0 mg/dL |
| 12.  | Serum calcium           | 9.2 mg/dL | 8-10 mg/dL |
| 13.  | Blood urea              | 42 mg/dL | 18-45 mg/dL |
| 14.  | Creatinine              | 1.1 mg/dL | 0.6-1.2 mg/dL |
| 15.  | Serum potassium         | 4.91 mmol/L | 3.5-5.1 mmol/L |
| 16.  | Alanine transaminase    | 33 U/L | 10-50 U/L |
| 17.  | Serum TSH levels        | 3.34 uIU/mL | 0.3-4.2 uIU/mL |
| 18.  | Serum triglycerides     | 300 mg/dL | <200 mg/dL |
| 19.  | Cholesterol             | 228 mg/dL | <200 mg/dL |
| 20.  | Viral profile           | Anti-HIV (ICT) Negative | - |
|      |                         | Anti-HCV (ICT) Negative | - |
|      |                         | HBsAg Negative | - |

TLC: total leukocyte count; DLC: differential leukocyte count; RDW: red cell distribution width; HIV: human immunodeficiency virus; HCV: hepatitis C virus; HBsAg: hepatitis B surface antigen; ICT: information and communication technology; TSH: thyroid-stimulating hormone

A CT scan of abdomen and pelvis (with contrast) was done on March 9, 2022, as described in (Table 2). This revealed enlarged liver and multiple enlarged lymph nodes; however, normal spleen, pancreas, and biliary tract. CT chest and neck done on March 9, 2022, showed multiple enlarged axillary and mediastinal lymph nodes (Figures 1, 2).
| S.n. | Structure             | Impression                                                                                                                                 |
|------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| 1.   | Liver                 | Enlarged measuring 16 cm in size, a hypodense, well-defined lesion measuring 18x16 mm was seen in segment 8 of the right lobe of liver.          |
| 2.   | Spleen                | Enlarged measuring 17.1 cm with wedge-shaped splenic infarcts.                                                                                |
| 3.   | Lymph nodes           | Multiple enlarged lymph nodes at the porta hepatitis, celiac axis, peri-pancreatic, pre- and para-aortic, and pre-caval region were seen. Largest lymph node measuring 3.8x4.1 cm at porta hepatitis is anteriorly compressing the second part of duodenum and posteriorly compressing and displacing IVC. |
| 4.   | Gallbladder and biliary tract | Normal                                                                                                                                  |

**TABLE 2: CT abdomen and pelvis findings of the patient.**

IVC: inferior vena cava

**FIGURE 1:** Hypodense lesion of 18x16 mm in segment 8 of liver as primary hepatic lymphoma (contrast in arterial phase).
FIGURE 2: Hypodense lesion of 18x16 mm in segment 8 of liver as primary hepatic lymphoma (contrast in venous phase).

CT scan chest and neck (metastatic workup) done on January 4, 2022, showed multiple enlarged axillary and mediastinal lymph nodes described in Table 3. Axillary lymphadenopathy and mediastinal lymphadenopathies are shown in Figures 3, 4.

| S.n.  | Structure           | Impression                                                                 |
|-------|---------------------|-----------------------------------------------------------------------------|
| 1.    | Cervical lymph nodes| No cervical lymphadenopathy.                                                |
| 2.    | Axillary lymph nodes| Enlarged bilateral axillary nodes were seen, the largest measuring 11.1 mm was seen in the right axilla. |
| 3.    | Mediastinal lymph nodes | Enlarged mediastinal nodes were seen, the largest measuring 19 mm was seen in the right para tracheal region. |
| 4.    | Lungs               | Atelectatic bands were seen in both lungs; however, no nodules or mass noted. |

TABLE 3: CT neck and chest findings of the patient.
Biopsy and histopathology reports are described in Table 4 and Figures 5-9 and have been labeled. Ultrasound-guided core biopsy of sub-hepatic lymph node was done and histopathology showed diffuse infiltrate of intermediate to large-sized round to oval cells with scanty cytoplasm and darkly stained nuclei with open chromatin and occasional prominent nuclei consistent with diffuse large B-cell lymphoma. Immunohistochemistry slides have been shown in Figures 1-7.
1. **Gross**
   Three tan-white colored cores and two core fragments measuring 0.5x0.2 cm.

2. **Microscopic**
   Diffuse infiltrates intermediate to large-sized round to oval cells with scant cytoplasm and darkly stained nuclei with open chromatin and occasional prominent nuclei consistent with diffuse large B-cell lymphoma.

3. **Immunohistochemistry**
   Immunohistochemistry showed CD-20, Bcl-2, Bcl-6, MUM-1, and c-MYC positive in 30% of cells and Ki-7 in 70% of cells; however, CD-10 and CD-3 were negative.

### TABLE 4: Histopathology report findings of the patient.

| S.n. | Study                  | Impression                                                                                                                                 |
|------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| 1.   | Gross                  | Three tan-white colored cores and two core fragments measuring 0.5x0.2 cm.                                                              |
| 2.   | Microscopic            | Diffuse infiltrates intermediate to large-sized round to oval cells with scant cytoplasm and darkly stained nuclei with open chromatin and occasional prominent nuclei consistent with diffuse large B-cell lymphoma. |
| 3.   | Immunohistochemistry   | Immunohistochemistry showed CD-20, Bcl-2, Bcl-6, MUM-1, and c-MYC positive in 30% of cells and Ki-7 in 70% of cells; however, CD-10 and CD-3 were negative. |

**FIGURE 5: Gross sub-hepatic lymph nodes biopsy specimen received through excisional biopsy.**
FIGURE 6: Low magnified LM specimen of lymph node of DLBCL.

The image is showing diffuse infiltration of malignant lymphoid cells with disorganization of typical nodal architecture. In the upper left segment of the specimen, the tumor has invaded outside the capsule to soft tissues.

DBCL: diffuse large B-cell lymphoma; LM: light microscopy

FIGURE 7: Magnified image of specimen showing diffuse large B-cell lymphoma.

The image is showing nests of large to medium-sized neoplastic B cells having large nuclei (as compared to histiocytes and small lymphocytes), high nuclear-cytoplasmic (N/C) ratio, and having highly basophilic stained cytoplasm. These nests of cells are separated by a fibrillary matrix of stroma.
Treatment and follow-up visit

The patient is on rituximab with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-DA-EPOCH) therapy described in Table 5.
S.n. | Drug administered | Route | Dosage | Duration
--- | --- | --- | --- | ---
1. | Rituximab (loading) | Intravenous | 100 mg | 1 day
2. | Rituximab | Intravenous | 500 mg | 1 day
3. | Etoposide | Intravenous | 80 mg | 4 days
4. | Deltacortril | Oral | 5 mg | 5 days
5. | Vincristine | Intravenous | 0.6 mg | 4 days
6. | Cyclophosphamide | Intravenous | 1,200 mg | 1 day
7. | Doxorubicin | Intravenous | 16 mg | 4 days
8. | Dexamethasone | Intravenous | 4 mg/mL | 1 day
9. | Omeprazole | Intravenous | 40 mg | SOS
10. | Ondansetron | Intravenous | 8 mg | SOS
11. | Gravimate | Intravenous | 50 mg | SOS
12. | Home treatment | | | |
   (1) Cefixime | Oral | 400 mg | 5 days
   (2) Ampogil | S/C injection | 300 mg | 3 days
   (3) Onset | Oral | 8 mg | 5 days
   (4) Omeprazol | Oral | 40 mg | 7 days
   (5) Tramal | Oral | 50 mg | Continue
   (6) Nystatin drops | Oral | 100,000 u/mL | 5 days

**TABLE 5: Treatment received by the patient.**

The patient presented again on January 17, 2022, having completed his first cycle of chemotherapy on January 10, 2022, with fever and generalized weakness. His lab investigations at admission showed total leukocyte count (TLC) of 0.28x10^3/μL with 10.9% neutrophils and 75% lymphocytes, hemoglobin of 6.8 g/dL, and platelets of 39x10^3/μL. He was started on broad-spectrum antibiotics, supportive treatment, and three red cell concentrate (RCC) transfusions were done. On discharge from the hospital on March 20, 2022, his hemoglobin was improved to 8.16 g/dL, TLC to 3.39x10^6/μL, with neutrophils 71% and lymphocytes 16%, while his platelets were raised to 54x10^3/μL. Apart from slightly raised bilirubin of 2.8 mg/dL, his other laboratory reports including renal function tests were normal.

**Signs and symptoms of primary Hodgkin’s lymphoma**

Non-Hodgkin’s lymphoma has symptoms such as fever, weight loss, abdominal pain, chest pain due to enlargement of lymph nodes in mediastinum, swollen abdomen, early satiety, and mild cough. Sometimes it is associated with recurrent infections and easy bruising and fatigue [4,5]. DLBCL presents similarly to other subtypes of non-Hodgkin’s lymphomas but with some additional symptoms. These additional symptoms are variable and depend upon the type of DLBCL, its stage, and number of cycles of chemotherapy.

**Discussion**

Primary hepatic lymphoma (PHL) is a rare type of diffuse large B-cell lymphoma (DLBCL) comprising less than 1% of all extranodal DLBCL cases. Because of its rarity and unusual presentation, it is often clinically indistinguishable from other common diseases like malaria, hydatid cyst, viral hepatitis, hepatocellular carcinoma, hepatic adenoma, and hepatic metastasis [6]. Investigations like alpha-fetoprotein and carcinoembryonic antigen levels may help differentiate PHL from hepatocellular carcinoma but these tests lack sensitivity and specificity [7,8]. Radiological imaging like ultrasound and computed tomography (CT) scans can reveal hypointense or hyperintense hepatic lesions and whether the lesion is unifocal, multifocal, or hepatic parenchyma is diffusely involved with coarse echotexture as in cirrhosis. However, like lab investigations, radiological imaging modalities too have limitations with regards to definitive diagnosis of PHL, which can be easily diagnosed with ultrasound or CT guided core biopsy of liver revealing diffuse infiltration intermediate to large sized round to oval cells with scant cytoplasm and darkly stained nuclei with open chromatin and occasional prominent nucleoli.
Immunohistochemistry of biopsied specimen can further aid in diagnosing PHL which will show cluster of differentiation (CD)-20 positivity, B-cell lymphoma 2 (Bcl-2), Bcl-6, multiple myeloma oncogene-1 (MUM-1), c-myelocytomatosis oncogene (c-MYC) positivity in 30-50% cases, sometimes CD-19 and CD-21 as well that is consistent with B-cell markers [9,10]. Treatment primarily consists of chemotherapy with R-CHOP regimen that includes rituximab, cyclophosphamide, hydroxydaunorubicin, Oncovins, such as vincristine, prednisone, and sometimes etoposide [11]. Frequent follow-up visits for treatment response and management of chemotherapy-related side effects are crucial for improved health care outcomes including patient satisfaction and prevention of complications.

Conclusions
One of the differentials for the space-occupying lesions in the liver is primary hepatic lymphoma if other malignancies are ruled out. Early diagnosis of PHL is not a difficult task if lymph node excisional biopsy is taken following detection on ultrasound or CT scan which will lead to early treatment initiation, early disease remission with improved long-term survival, and cost-effective health care.

Additional Information

Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Swerdlow SH, Campo E, Pileri SA, et al.: The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016, 127:2375-90. 10.1182/blood-2016-01-643569
2. Shi Y, Han Y, Yang J, et al.: Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res. 2019, 31:152-61. 10.21147/jissn.1000-9604.2019.01.10
3. Gorodetskiy V, Klapper W, Probatova N, Vasilyev V: Primary diffuse large B-cell lymphoma of the liver in a patient with Sjogren syndrome. Case Rep Oncol Med. 2016, 2016: 10.1155/2016/2053257
4. Sapkota S, Shaikh H: Non-Hodgkin lymphoma. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2022.
5. Sun R, Medeiros LJ, Young KH: Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol. 2016, 29:1118-42. 10.1038/modpathol.2016.92
6. Resende V, Oliveira TS, Laboissemière RS, Tavares-Junior WC, de Melo Couto OF: Primary hepatic lymphoma: a case report. Int J Surg Case Rep. 2013, 4:1166-8. 10.1016/j.jscr.2013.10.005
7. Lohana AK, Tariq MA, Abid S: Hepatic lymphoma. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2022.
8. Patel TS, Malvania R, Shah MC, Shah MI, Gami AG: Primary hepatic lymphoma: a case report. J Cytol. 2015, 52:56-8. 10.4103/0970-9371.155232
9. Primary hepatic lymphoma. (2022). Accessed: March 6, 2022: https://doi.org/10.5334/jid-7581.
10. Mysteri D, Dellaportas D, Arkounani E, Marinis A, Zizi-Sermpetzoglou A: Primary hepatic lymphoma: a challenging diagnosis. Case Rep Oncol Med. 2014, 2014: 10.1155/2014/212598
11. Yang H, Yang Z, Sang X, Mao Y, Lu X, Zhong S, Xu H: Diagnosis and treatment of primary hepatic lymphoma. Transl Cancer Res. 2018, 7;10.21037/tcr.2018.06.05